01
What the evidence says
The randomized trial compared a hearing intervention with a health-education control in 977 adults aged 70–84 with untreated hearing loss. Over three years, change in the global cognition score did not differ significantly in the combined study population. In a prespecified analysis, the effect differed between the healthier volunteer cohort and the ARIC cohort, which had greater baseline risk of cognitive decline.
Sources for this section: [1]
02
How to use the finding
The trial strongly supports treating hearing loss for communication and quality-of-life reasons when appropriate; those benefits do not depend on proving dementia prevention. For cognitive protection, the subgroup finding is promising for people at higher risk but should not be converted into a universal guarantee. Hearing aids, assistive technology, communication training, cost, fit, and continued support all influence real-world benefit.
Sources for this section: [1]
03
Limits and open questions
Subgroup effects can arise by chance even when planned, and the two recruitment cohorts differed in many ways. Three years may be short for dementia outcomes, while the intervention was more comprehensive than simply purchasing a device. Replication and longer follow-up should determine whether baseline cognitive risk truly modifies the effect.
Sources for this section: [1]
Sources
- Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE)The Lancet · 2023DOI 10.1016/S0140-6736(23)01406-X